1. Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival 
Daniel Weisdorf, Stephen Spellman, Michael Haagenson, Mary Horowitz, Stephanie Lee, Claudio Anasetti, Michelle Setterholm, Rebecca Drexler, Martin Maiers, Roberta King, Dennis Confer, John Klein 
Biology of Blood and Marrow Transplantation 
Volume 14, Issue 7, Pages (July 2008)
DOI: /j.bbmt
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Estimated 1-year survival for a first transplant, under 18 years old, CMV-negative patient with a 25-year-old donor. The patient is assumed to be White with a KPS of , transplanted in using myeloablative conditioning and tacrolimus/methotrexate as GVHD prophylaxis. The 21 groups cluster (per Table 2) as: well matched (thin/blue lines); partially matched (thick/red lines); and mismatched (medium/green lines). Right panel in color for website display.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Estimated survival for different patients undergoing a first transplant. Patients are all assumed to be CMV negative, White, with a KPS of , transplanted in receiving tacrolimus/methotrexate as GVHD prophylaxis and a 25-year-old donor. All transplants are assumed myeloablative except the 55-year-old late MDS patient who was assumed to have a reduced-intensity transplant. Patients' age, disease, and disease stage are as shown in each panel.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Estimated 5-year survival for different patients undergoing a first transplant. Patients are assumed to be CMV negative, White, with a KPS of , transplanted in receiving tacrolimus/methotrexate as GVHD prophylaxis and a 25-year-old donor. All transplants are assumed myeloablative except the 55-year-old late MDS patient who was assumed to have a reduced-intensity transplant. Patients' age, disease, and disease stage are as shown in each panel.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions